Mga Batayang Estadistika
| LEI | 5493008O4R82Q4STJ936 |
| CIK | 1083446 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Astrana Health, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Exhibit 10.2 Astrana July 1, 2025 Prospect Medical Holdings, Inc. 3828 Delmas Terrace Culver City, CA 90232 Attention: Von Crockett, Chief Executive Officer Re: Closing and Post-Closing Reconciliation of Indemnification and Other Matters Dear Mr. Crockett, This Side Letter (this “Side Letter”) is delivered to Prospect Medical Holdings, Inc., a Delaware corporation (the “Seller Representative”) on |
|
| August 7, 2025 |
Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2025 Results Company to Host Conference Call on Thursday, August 7, 2025, at 2:30 p.m. PT/5:30 p.m. ET · Reports total revenue of $654.8 million and adjusted EBITDA of $48.1 million, both at the higher end of guidance · Continues to manage medical cost trends effectively, with trend within expectations across all lines of business · Reiterat |
|
| August 7, 2025 |
Supplemental Data of Astrana Health, Inc., dated August 7, 2025. Exhibit 99.2 |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 ASTRANA HEALTH, INC. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Astrana Health, Inc. |
|
| July 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 1, 2025 ASTRANA HEALTH, INC. |
|
| July 2, 2025 |
Astrana Health Announces Closing of Prospect Health Acquisition Exhibit 99.1 Astrana Health Announces Closing of Prospect Health Acquisition ALHAMBRA, Calif., July 2, 2025 /PRNewswire/ - Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technology-enabled healthcare company empowering providers to deliver accessible, high-quality, and high-value care to all, today an |
|
| June 13, 2025 |
As filed with the Securities and Exchange Commission on June 13, 2025 S-8 1 tm2517534d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on June 13, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 Astrana Health, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation or org |
|
| June 13, 2025 |
Calculation of Filing Fee Tables S-8 Astrana Health, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 2,000,000 $ 25.19 $ 50,380,000.00 0.0001531 $ 7,713.18 Total Offe |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2025 ASTRANA HEALTH, INC. |
|
| June 11, 2025 |
Astrana Health, Inc. Amended and Restated 2024 Equity Incentive Plan. Exhibit 10.1 ASTRANA HEALTH, INC. AMENDED AND RESTATED 2024 EQUITY INCENTIVE PLAN 1. Establishment, Purpose, Duration. (a) Establishment. Astrana Health, Inc. (the “Company”) originally established the Astrana Health, Inc. 2024 Equity Incentive Plan, effective as of February 28, 2024 (the “Effective Date”), subject to the approval of the Plan by the stockholders of the Compa |
|
| June 4, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 4, 2025 ASTRANA HEALTH, INC. |
|
| June 4, 2025 |
Exhibit 99.1 ••••• |
|
| May 13, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2025 ASTRANA HEALTH, INC. |
|
| May 13, 2025 |
Exhibit 99.1 2019 2020 2021 2022 2023 2024 2025E 2019 2020 2021 2022 2023 2024 2025E •••••••• 2019 2024 2027E ••••• 2021 2022 2023 2024 2025 Q1 2025E 2025 |
|
| May 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Astrana Health, Inc. ( |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2025 ASTRANA HEALTH, INC. |
|
| May 8, 2025 |
Exhibit 99.1 Astrana Health, Inc. Reports First Quarter 2025 Results Company to Host Conference Call on Thursday, May 8, 2025, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 8, 2025 /PRNewswire/ - Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling |
|
| May 8, 2025 |
Exhibit 99.2 May 2025 First Quarter 2025 Earnings Supplement 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operatin |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2025 ASTRANA HEALTH, INC. |
|
| March 14, 2025 |
Exhibit 99.2 March 2025 Fourth Quarter & Full Year 2024 Earnings Supplement 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial cond |
|
| March 14, 2025 |
ASTRANA HEALTH, INC. CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) Exhibit 99.1 ASTRANA HEALTH, INC. CONSOLIDATED BALANCE SHEETS (IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA) December 31, 2024 December 31, 2023 (Unaudited) (Audited) Assets Current assets Cash and cash equivalents $ 288,455 $ 293,807 Investment in marketable securities 2,378 2,498 Receivables, net 225,733 76,780 Receivables, net – related parties 50,257 58,980 Income taxes receivable 19,316 10,6 |
|
| March 14, 2025 |
Description of Registered Securities. Exhibit 4.1 DESCRIPTION OF ASTRANA HEALTH, INC. REGISTERED SECURITIES The following summarizes the terms and provisions of the common stock of Astrana Health, Inc., a Delaware corporation (the “Company”), which common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The summary does not purport to be complete and is qualified in its enti |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to . Commission file number: 001-37392 Astrana Heal |
|
| March 14, 2025 |
Exhibit 10.48 EMPLOYMENT AGREEMENT (Amended and Restated as of January 31, 2025) This EMPLOYMENT AGREEMENT (this “Agreement” including Exhibits and Schedules) by and between Astrana Health, Inc., a Delaware corporation (the “Employer”), and Dinesh Kumar, MD (the “Employee,” and together with Employer, collectively referred to as the “Parties”) amends and restates and supersedes in its entirety, ef |
|
| March 14, 2025 |
Subsidiaries of Astrana Health, Inc. Exhibit 21.1 Subsidiaries The entity names below are as of March 14, 2025: Entity Jurisdiction of Incorporation Astrana Health Management, Inc. California Community Family Care Health Plan California Astrana Health Technologies, Inc. Delaware APAACO, Inc. Delaware Metropolitan IPA California Golden Triangle Physician Alliance, Texas Heritage Physician Networks Texas For your Benefit, Inc. Californ |
|
| March 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2025 (February 27, 2025) ASTRANA HEALTH, INC. |
|
| March 14, 2025 |
Exhibit 99.2 STOCK REPURCHASE AGREEMENT This STOCK REPURCHASE AGREEMENT (this “Agreement’) is made and entered into as of December 10, 2024 (the “Effective Date”), by and between ASTRANA HEALTH, INC., a Delaware corporation (the “Company”), and MITCHELL W. KITAYAMA, an individual (the “Selling Stockholder” and together with the Company, the “Parties” and each a “Party”). RECITALS The Selling Stock |
|
| March 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 10, 2025 ASTRANA HEALTH, INC. |
|
| March 10, 2025 |
Exhibit 99.1 Investor Presentation March 2025 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plan |
|
| March 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 3, 2025 ASTRANA HEALTH, INC. |
|
| March 3, 2025 |
Exhibit 99.1 • • • • • • • • • • • • • • • • • • • • • |
|
| February 27, 2025 |
Exhibit 99.2 February 2025 Fourth Quarter & Full Year 2024 Earnings Supplement 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial c |
|
| February 27, 2025 |
Exhibit 10.2 AMENDED AND RESTATED GUARANTY AND SECURITY AGREEMENT dated as of February 26, 2025 made by ASTRANA HEALTH, INC. as Borrower and The other Grantors From Time to Time Party Hereto in favor of TRUIST BANK as Administrative Agent TABLE OF CONTENTS Page(s) ARTICLE I Definitions 2 Section 1.1 Definitions 2 Section 1.2 Other Definitional Provisions; References 5 ARTICLE II Guarantee 6 Sectio |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2025 ASTRANA HEALTH, INC. |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2025 ASTRANA HEALTH, INC. |
|
| February 27, 2025 |
Exhibit 99.1 Astrana Health, Inc. Reports Fourth Quarter and Year-End 2024 Results Company to Host Conference Call on Thursday, February 27, 2025, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., February 27, 2025 /PRNewswire/ - Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a leading provider-centric, technology-powered he |
|
| February 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-37392 CUSIP NUMBER 03763A207 (Check one): x Form 10-K o Form 20-F o Form 11-K ¨ Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: December 31, 2024 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Tra |
|
| February 27, 2025 |
Exhibit 10.1 Deal CUSIP: 04635HAA5 Revolver CUSIP: 04635HAB3 Term A Loan CUSIP: 04635HAD9 Delayed Draw Term Loan CUSIP: 04635HAC1 SECOND AMENDED AND RESTATED CREDIT AGREEMENT dated as of February 26, 2025 among ASTRANA HEALTH, INC. as Borrower THE LENDERS FROM TIME TO TIME PARTY HERETO TRUIST BANK as Administrative Agent WELLS FARGO SECURITIES, LLC and TRUIST SECURITIES, INC., as Co-Sustainability |
|
| February 18, 2025 |
EX-99.1 2 tm253768d2ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Schedule A Capitalized terms used but not defined in this Schedule A shall have the meanings set forth in the Schedule 13D of which this Schedule A is an exhibit. The following table sets forth the name, position, address, principal occupation and citizenship or jurisdiction of each executive officer and director of the Reporting Person: Nam |
|
| January 22, 2025 |
Exhibit 99.1 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of January 17, 2025 by and between Allied Physicians of California, a Professional Medical Corporation, a California corporation (“APC”), and Astrana health, Inc., a Delaware corporation (“Astrana”), with reference to the following facts: A. APC holds more than 300,000 shares of |
|
| January 21, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 17, 2025 ASTRANA HEALTH, INC. |
|
| January 21, 2025 |
Exhibit 10.1 STOCK REPURCHASE AGREEMENT THIS STOCK REPURCHASE AGREEMENT (this “Agreement”) is entered into as of January 17, 2025 by and between Allied Physicians of California, a Professional Medical Corporation, a California corporation (“APC”), and Astrana health, Inc., a Delaware corporation (“Astrana”), with reference to the following facts: A. APC holds more than 300,000 shares of |
|
| January 14, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 14, 2025 ASTRANA HEALTH, INC. |
|
| January 14, 2025 |
Exhibit 99.1 •••••••• ••••• |
|
| November 14, 2024 |
EX-99.1 2 tm2428476d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 •••••••• |
|
| November 14, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 14, 2024 ASTRANA HEALTH, INC. |
|
| November 12, 2024 |
Exhibit 99.1 STOCK REPURCHASE AGREEMENT This STOCK REPURCHASE AGREEMENT (this “Agreement’) is made and entered into as of August 14, 2024 (the “Effective Date”), by and between ASTRANA HEALTH, INC., a Delaware corporation (the “Company”), and DAVID G. SCHMIDT, an individual (the “Selling Stockholder” and together with the Company, the “Parties” and each a “Party”). RECITALS The Selling Stockholder |
|
| November 12, 2024 |
Form of Restricted Stock Agreement (2024 Non-Employee Director Award) (2024 Equity Incentive Plan) Exhibit 10.3 ASTRANA HEALTH, INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT NOTICE Astrana Health, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) the number of shares of the Company’s common stock, par value $0.001, set forth below (individually and collectively referred to as the “Restricted Share |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2024 ASTRANA HEALTH, INC. |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Astrana Health, In |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2024 ASTRANA HEALTH, INC. |
|
| November 8, 2024 |
Exhibit 10.1 TRUIST BANK TRUIST SECURITIES, INC. 3333 Peachtree Road 11th Floor, South Tower Atlanta, Georgia 30326 JPMORGAN CHASE BANK, N.A. 383 Madison Avenue New York, New York 10179 CONFIDENTIAL November 8, 2024 Project Prime Commitment Letter Astrana Health, Inc. 1668 S. Garfield Avenue, 2nd Floor Alhambra, CA 91801 Attention: Chandan Basho, Chief Financial Officer Email: chan |
|
| November 8, 2024 |
Exhibit 99.2 |
|
| November 8, 2024 |
Exhibit 99.1 Astrana Health Announces Definitive Agreement to Acquire Certain Businesses and Assets of Prospect Health System ALHAMBRA, Calif., November 8, 2024 /PRNewswire/ - Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver acce |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2024 ASTRANA HEALTH, INC. |
|
| November 8, 2024 |
Exhibit 2.1 ASSET AND EQUITY PURCHASE AGREEMENT BY AND AMONG PHP HOLDINGS, LLC, PHS HOLDINGS, LLC, PROSPECT INTERMEDIATE HOLDINGS, INC., THE ENTITIES SET FORTH ON SCHEDULE C.1 ATTACHED HERETO, PROSPECT MEDICAL HOLDINGS, INC., AS THE SELLER REPRESENTATIVE, ASTRANA HEALTH, INC., AND THE ENTITIES SET FORTH ON SCHEDULE C.2 ATTACHED HERETO DATED AS OF NOVEMBER 8, 2024 TABLE OF CONTENTS Page ARTICLE 1 P |
|
| November 7, 2024 |
Exhibit 99.1 Astrana Health, Inc. Reports Third Quarter 2024 Results Company to Host Conference Call on Thursday, November 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., November 7, 2024 /PRNewswire/ - Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company |
|
| November 7, 2024 |
Exhibit 99.2 Third Quarter 2024 Earnings Supplement November 2024 , :s / k A I of di Astrana Health Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's bu |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 ASTRANA HEALTH, INC. |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 4, 2024 ASTRANA HEALTH, INC. |
|
| September 4, 2024 |
Exhibit 99.1 •••••••• |
|
| September 4, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 4, 2024 ASTRANA HEALTH, INC. |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Astrana Health, Inc. (E |
|
| August 9, 2024 |
Exhibit 10.10 AMENDMENT NO. 2 to STOCK PURCHASE AGREEMENT THIS AMENDMENT (this “Amendment”), is entered into as of June 25, 2024, by and among ASTRANA HEALTH MANAGEMENT, INC., a California corporation f/k/a NETWORK MEDICAL MANAGEMENT, INC. (“Buyer”); RONALD BRANDT (“Ron Brandt”) and ALLISON BRANDT (“Allison Brandt”), each in their individual capacities (as, the “Beneficial Owners”) and in their ca |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 ASTRANA HEALTH, INC. |
|
| August 7, 2024 |
Exhibit 99.2 Exhibit 99.2 |
|
| August 7, 2024 |
Exhibit 99.1 Astrana Health, Inc. Reports Second Quarter 2024 Results Company to Host Conference Call on Wednesday, August 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., August 7, 2024 /PRNewswire/ - Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company e |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 24, 2024 ASTRANA HEALTH, INC. |
|
| July 25, 2024 |
Astrana Health Enters Definitive Agreement to Acquire Collaborative Health Systems Exhibit 99.1 FOR IMMEDIATE RELEASE Astrana Health Enters Definitive Agreement to Acquire Collaborative Health Systems ALHAMBRA, Calif., July 25, 2024 – Astrana Health, Inc. (“Astrana”), together with its subsidiaries and affiliated entities (“the Company”) (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and h |
|
| July 25, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG ASTRANA HEALTH, INC., APOLLOCARE PARTNERS OF TEXAS 2, UNIVERSAL AMERICAN CORP., HERITAGE HEALTH SYSTEMS OF TEXAS, INC., AND HERITAGE HEALTH SYSTEMS, INC. Dated as of July 24, 2024 TABLE OF CONTENTS Page ARTICLE I. PURCHASE AND SALE 5 Section 1.1 Purchase and Sale of the Purchased Interests 5 Section 1.2 Closing 5 ARTICLE II. OTHER CLOSING TRA |
|
| July 15, 2024 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(7) (Form Type) Astrana Health, Inc. |
|
| July 15, 2024 |
ASTRANA HEALTH, INC. 341,416 Shares of Common Stock Filed Pursuant to Rule 424(b)(7) Registration No. 333-274013 PROSPECTUS SUPPLEMENT (To Prospectus dated August 16, 2023) ASTRANA HEALTH, INC. 341,416 Shares of Common Stock This prospectus supplement relates to the potential offer and sale from time to time by the selling stockholders identified in this prospectus supplement of up to 341,416 shares of our common stock, par value $0.001 per share, |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2024 ASTRANA HEALTH, INC. |
|
| June 13, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF ASTRANA HEALTH, INC. Astrana Health, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: Article X, Section (a) of the Restated Certificate of Incorporation of the Corporation (the “Certificat |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 13, 2024 ASTRANA HEALTH, INC. |
|
| June 12, 2024 |
Exhibit 10.4 ASTRANA HEALTH, INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT NOTICE Astrana Health, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) the number of shares of the Company’s common stock, par value $0.001, set forth below (individually and collectively referred to as the “Restricted Share |
|
| June 12, 2024 |
Astrana Health, Inc. 2024 Equity Incentive Plan. Exhibit 10.1 ASTRANA HEALTH, INC. 2024 EQUITY INCENTIVE PLAN 1. Establishment, Purpose, Duration. (a) Establishment. Astrana Health, Inc. (the “Company”) hereby establishes an equity compensation plan to be known as the Astrana Health, Inc. 2024 Equity Incentive Plan (the “Plan”), effective as of February 28, 2024 (the “Effective Date”), subject to the approval of the Plan by the stockhold |
|
| June 12, 2024 |
Exhibit 10.2 ASTRANA HEALTH, INC. 2024 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION GRANT NOTICE Astrana Health, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option (the “Option”) to purchase the number of shares of the Company’s common stock, par value $0.001 (“Shares”), set forth below for the exerc |
|
| June 12, 2024 |
Exhibit 10.5 ASTRANA HEALTH, INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Astrana Health, Inc., a Delaware corporation (together with any successor thereof, the “Company”), pursuant to its 2024 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of restricted stock units set forth below (individ |
|
| June 12, 2024 |
Exhibit 10.3 ASTRANA HEALTH, INC. 2024 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION GRANT NOTICE Astrana Health, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option (the “Option”) to purchase the number of shares of the Company’s common stock, par value $0.001 (“Shares”), set forth below for the ex |
|
| June 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 12, 2024 ASTRANA HEALTH, INC. |
|
| June 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Astrana Health, Inc. |
|
| June 12, 2024 |
As filed with the Securities and Exchange Commission on June 12, 2024 As filed with the Securities and Exchange Commission on June 12, 2024 Registration No. |
|
| May 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 20, 2024 ASTRANA HEALTH, INC. |
|
| May 21, 2024 |
Exhibit 10.1 FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FOURTH AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT, dated as of May 20, 2024 (this “Amendment”), is made by and among ASTRANA HEALTH, INC. (f/k/a Apollo Medical Holdings, Inc.), a Delaware corporation (the “Borrower”), ASTRANA HEALTH MANAGEMENT, INC. (f/k/a Network Medical Management, Inc.), a California corporation |
|
| May 15, 2024 |
Exhibit 99.1 May 2024 Powered by Technology. Built by Doctors. For Patients. 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial con |
|
| May 15, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2024 ASTRANA HEALTH, INC. |
|
| May 9, 2024 |
pg. 1 INDEPENDENT CONTRACTOR AGREEMENT This Independent Contractor Agreement (“Agreement”) is dated effective as of December 1, 2023 (the “Effective Date”), by and between AMG, a California Professional Medical Corporation (“Group”), and Thomas S Lam, M.D., A Professional Corporation (“Provider’’). Recitals: WHEREAS, Group is a professional corporation organized under the laws of the State of Cali |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Astrana Health, Inc. ( |
|
| May 7, 2024 |
Exhibit 99.1 Astrana Health, Inc. Reports First Quarter 2024 Results Company to Host Conference Call on Tuesday, May 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 7, 2024 /PRNewswire/ - Astrana Health, Inc. (“Astrana,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling p |
|
| May 7, 2024 |
Exhibit 99.2 May 2024 Q1 2024 Update Q1 2024 Earnings Supplement 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, oper |
|
| May 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 7, 2024 ASTRANA HEALTH, INC. |
|
| April 24, 2024 |
Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A CONVERTIBLE PREFERRED STOCK AND SERIES B CONVERTIBLE PREFERRED STOCK OF ASTRANA HEALTH, INC. (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) Astrana Health, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 151(g) |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy State |
|
| April 24, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 24, 2024 ASTRANA HEALTH, INC. |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 23, 2024 ASTRANA HEALTH, INC. |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 5, 2024 |
Exhibit 10.1 EMPLOYMENT AGREEMENT (Amended and Restated as of April 2, 2024) This EMPLOYMENT AGREEMENT (this “Agreement”) by and between Astrana Health, Inc., a Delaware corporation (the “Employer”), and Brandon Sim (the “Employee,” and together with the Employer, collectively referred to as the “Parties”), amends and restates and supersedes in its entirety, effective as of April 2, 2024 (the “Res |
|
| April 5, 2024 |
Exhibit 10.2 EMPLOYMENT AGREEMENT (Amended and Restated as of April 2, 2024) This EMPLOYMENT AGREEMENT (this “Agreement”) by and between Astrana Health, Inc., a Delaware corporation (the “Employer”), and Chandan Basho (the “Employee,” and together with the Employer, collectively referred to as the “Parties”), amends and restates and supersedes in its entirety, effective as of April 2, 2024 (the “R |
|
| April 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 2, 2024 ASTRANA HEALTH, INC. |
|
| April 2, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 29, 2024 ASTRANA HEALTH, INC. |
|
| April 2, 2024 |
Exhibit 10.1 AMENDMENT NO. 2 to ASSET AND EQUITY PURCHASE AGREEMENT THIS AMENDMENT (this “Amendment”), is entered into as of March 29, 2024, by and among Metropolitan IPA, a California professional corporation (“PC Buyer”); ASTRANA HEALTH ENABLEMENT OF CA LLC, a California limited liability company (“MSO GP Buyer”); ASTRANA HEALTH MANAGEMENT, INC., a California corporation (“MSO LP Buyer” and, tog |
|
| April 2, 2024 |
Exhibit 10.2 AMENDMENT NO. 1 to STOCK PURCHASE AGREEMENT THIS AMENDMENT (this “Amendment”), is entered into as of March 31, 2024, by and among ASTRANA HEALTH MANAGEMENT, INC., a California corporation f/k/a Network Medical Management, Inc. (“Buyer”); RONALD BRANDT (“Ron Brandt”) and ALLISON BRANDT (“Allison Brandt”), each in their individual capacities (as, the “Beneficial Owners”) and in their ca |
|
| March 11, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 11, 2024 ASTRANA HEALTH, INC. |
|
| March 11, 2024 |
March 2024 Powered by Technology. Built by Doctors. For Patients. Exhibit 99.1 March 2024 Powered by Technology. Built by Doctors. For Patients. 2 Forward Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about the Company's business, financi |
|
| February 29, 2024 |
Exhibit 10.62 THIS NOTE HAS NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR WITH ANY SECURITIES REGULATORY AUTHORITY OR ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES. THIS NOTE IS SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED, RESOLD, PLEDGED, ASSIGNED OR OTHERWISE DISPOSED OF EXCEPT PURSUA |
|
| February 29, 2024 |
Exhibit 10.1 ASTRANA HEALTH, INC. 2015 EQUITY INCENTIVE PLAN (Amended and Restated Effective February 26, 2024) 1. Purpose, History and Effective Date. (a) Purpose. The Astrana Health, Inc. 2015 Equity Incentive Plan has two complementary purposes: (i) to attract and retain outstanding individuals to serve as officers, employees, directors or consultants and (ii) to increase stockholder value. The |
|
| February 29, 2024 |
PHYSICIAN SHAREHOLDER AGREEMENT This PHYSICIAN SHAREHOLDER AGREEMENT (this "Agreement"), dated as of August 31, 2023, is granted and delivered by Thomas Lam, M. |
|
| February 29, 2024 |
Exhibit 3.1 ASTRANA HEALTH, INC. AMENDED AND RESTATED BY-LAWS Amended and restated as of February 28, 2024 TABLE OF CONTENTS ARTICLE I - OFFICES 1 Section 1.1 - Principal Office 1 Section 1.2 - Other Offices 1 ARTICLE II - SHAREHOLDERS 1 Section 2.1 - Annual Meeting 1 Section 2.2 - Special Meetings 1 Section 2.3 - Notice of Meetings 1 Section 2.4 - Quorum 2 Section 2.5 - Organization 2 Section 2.6 |
|
| February 29, 2024 |
Exhibit 10.4 ASTRANA HEALTH, INC. OPTION CERTIFICATE (Incentive Stock Option) THIS IS TO CERTIFY that Astrana Health, Inc., a Delaware corporation (the “Company”), has granted to the individual named below (“Optionee”) an incentive stock option (the “Option”) to purchase shares of the Company’s Common Stock (the “Shares”) under its 2015 Equity Incentive Plan (the “Plan”) and upon the terms and con |
|
| February 29, 2024 |
Form of Restricted Stock Unit Agreement (2015 Equity Incentive Plan). Exhibit 10.3 ASTRANA HEALTH, INC. 2015 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Astrana Health, Inc., a Delaware corporation (together with any successor thereof, the “Company”), pursuant to its 2015 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of restricted stock units set forth below (individ |
|
| February 29, 2024 |
Exhibit 4.1 DESCRIPTION OF ASTRANA HEALTH, INC. REGISTERED SECURITIES The following summarizes the terms and provisions of the common stock of Astrana Health, Inc., a Delaware corporation (the “Company”), which common stock is registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The summary does not purport to be complete and is qualified in its enti |
|
| February 29, 2024 |
Form of Stock Option Agreement (Employment Inducement Award Plan) (2024). Exhibit 10.57 ASTRANA HEALTH, INC. EMPLOYMENT INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE Astrana Health, Inc. (the “Company”), pursuant to its Employment Inducement Award Plan (the “Plan”), hereby grants to the individual listed below (“Participant”), as an inducement to Participant’s commencement of employment with the Company or a Subsidiary, an option (the “Option”) to purchase the number |
|
| February 29, 2024 |
Form of Nonqualified Stock Option Agreement (2015 Equity Incentive Plan). Exhibit 10.5 ASTRANA HEALTH, INC. OPTION CERTIFICATE (Non-Qualified Stock Option) THIS IS TO CERTIFY that Astrana Health, Inc., a Delaware corporation (the “Company”), has granted to the individual named below (“Optionee”) a non-qualified stock option (the “Option”) to purchase shares of the Company’s Common Stock (the “Shares”) under its 2015 Equity Incentive Plan (the “Plan”) and upon the terms |
|
| February 29, 2024 |
Form of Restricted Stock Agreement (Employment Inducement Award Plan) (2024). Exhibit 10.58 ASTRANA HEALTH, INC. EMPLOYMENT INDUCEMENT AWARD PLAN RESTRICTED STOCK GRANT NOTICE Astrana Health, Inc. (the “Company”), pursuant to its Employment Inducement Award Plan (the “Plan”), hereby grants to the individual listed below (“Participant”), as an inducement to the Participant’s commencement of employment with the Company or a Subsidiary, the number of shares of the Company’s co |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to . Commission file number: 001-37392 Astrana Heal |
|
| February 29, 2024 |
Exhibit 10.48 ASTRANA HEALTH, INC. EMPLOYEE STOCK PURCHASE PLAN (Amended and Restated Effective February 26, 2024) 1. Establishment and Purpose of Plan. This Astrana Health, Inc. Employee Stock Purchase Plan (the “Plan”) was adopted by the Board effective April 21, 2023 and approved by the stockholders of the Company at the 2023 Annual Meeting of Stockholders. The purpose of the Plan is to provide |
|
| February 29, 2024 |
Astrana Health, Inc. Insider Trading Policy (last revised Exhibit 19.1 ASTRANA HEALTH, INC. INSIDER TRADING POLICY Astrana Health, Inc. (the “Company”) has adopted this Insider Trading Policy, which is designed to provide guidelines to all directors, officers and other personnel, whether employees, consultants or contractors, to the Company and its subsidiaries and affiliated entities, as appropriate, including variable interest entities (collectively, t |
|
| February 29, 2024 |
Nonqualified Deferred Compensation Plan (amended and restated effective February 26, 2024). Exhibit 10.49 ASTRANA HEALTH, INC. NONQUALIFIED DEFERRED COMPENSATION PLAN (Amended and Restated Effective February 26, 2024) RECITALS This Nonqualified Deferred Compensation Plan (the “Plan”) is adopted by Astrana Health, Inc. (the “Company”), a Delaware corporation, for the benefit of its Eligible Individuals. The purpose of the Plan is to offer selected Eligible Individuals who contribute signi |
|
| February 29, 2024 |
- 1 - LOAN AND SECURITY AGREEMENT This Loan and Security Agreement (this “Agreement”) is entered into on January 31, 2024, by and between AP-AMH 2 Medical Corporation, a California professional corporation (“Borrower”) and Apollo Medical Holdings, Inc. |
|
| February 29, 2024 |
Astrana Health, Inc. Compensation Recovery Policy (last revised February 26, 2024). Exhibit 97.1 ASTRANA HEALTH, INC. COMPENSATION RECOVERY POLICY (Last revised February 26, 2024) 1. Introduction The Board of Directors (the “Board”) of Astrana Health, Inc. (the “Company”) has adopted this Compensation Recovery Policy (the “Policy”), which provides for the recovery of certain executive compensation in the event of an accounting restatement resulting from material noncompliance wit |
|
| February 29, 2024 |
Subsidiaries of Astrana Health, Inc. (f/k/a Apollo Medical Holdings, Inc.) Exhibit 21.1 Subsidiaries The entity names below are as of February 29, 2024: Entity Jurisdiction of Incorporation Astrana Health Management, Inc. California Astrana Health Technologies, Inc. Delaware APAACO, Inc. Delaware Astrana Health Medical Corporation* California Astrana Care Partners Medical Corporation* California Allied Physicians of California, a Professional Medical Corporation* Califor |
|
| February 29, 2024 |
Form of Restricted Stock Agreement (2015 Equity Incentive Plan). Exhibit 10.2 ASTRANA HEALTH, INC. 2015 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT NOTICE Astrana Health, Inc., a Delaware corporation (together with any successor thereof, the “Company”), pursuant to its 2015 Equity Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), the number of shares of the Company’s common stock, par value $0. |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2024 ASTRANA HEALTH, INC. |
|
| February 29, 2024 |
- 1 - EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement” including Exhibits and Schedules) is made and entered into as of January 23, 2024, by and between ApolloCare Enablement of Nevada, a Nevada corporation (the “Employer”), and Dinesh Kumar, MD (the “Employee,” and together with Employer, collectively referred to as the “Parties”) with effect from and after the “Effective Date” as set forth in Section 22 below. |
|
| February 29, 2024 |
Exhibit 10.54 ASTRANA HEALTH, INC. EMPLOYMENT INDUCEMENT AWARD PLAN (Amended and Restated Effective February 26, 2024) ARTICLE I. PURPOSE This Plan was established effective as of November 15, 2023, the date of approval of the Plan by the Board. The Plan’s purpose is to enhance the Company’s ability to attract and motivate individuals who are expected to make important contributions to the Company |
|
| February 29, 2024 |
Form of Restricted Stock Unit Agreement (Employment Inducement Award Plan) (2024). Exhibit 10.59 ASTRANA HEALTH, INC. EMPLOYMENT INDUCEMENT AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Astrana Health, Inc., a Delaware corporation (together with any successor thereof, the “Company”), pursuant to its Employment Inducement Award Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”) the number of restricted stock units set forth b |
|
| February 29, 2024 |
Exhibit 3.2 ASTRANA HEALTH, INC. AMENDED AND RESTATED BY-LAWS Amended and restated as of February 2628, 2024 TABLE OF CONTENTS ARTICLE I - OFFICES 1 Section 1.1 - Principal Office 1 Section 1.2 - Other Offices 1 ARTICLE II - SHAREHOLDERS 1 Section 2.1 - Annual Meeting 1 Section 2.2 - Special Meetings 1 Section 2.3 - Notice of Meetings 1 Section 2.4 - Quorum 12 Section 2.5 - Organization 2 Section |
|
| February 27, 2024 |
Exhibit 99.2 Feb 2024 Q4 2023 Earnings Supplement 2 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, |
|
| February 27, 2024 |
Exhibit 99.1 Astrana Health, Inc. Reports Fourth Quarter and Year-End 2023 Results Company to Host Conference Call on Tuesday, Feb. 27, 2024, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., February 27, 2024 /PRNewswire/ - Astrana Health, Inc. (together with its subsidiaries and affiliated entities, “Astrana”) (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company focused |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 27, 2024 ASTRANA HEALTH, INC. |
|
| February 26, 2024 |
Amended and Restated By-Laws (effective February 26, 2024). Exhibit 3.1 ASTRANA HEALTH, INC. AMENDED AND RESTATED BY-LAWS Amended and restated as of February 26, 2024 TABLE OF CONTENTS ARTICLE I - OFFICES 1 Section 1.1 - Principal Office 1 Section 1.2 - Other Offices 1 ARTICLE II - SHAREHOLDERS 1 Section 2.1 - Annual Meeting 1 Section 2.2 - Special Meetings 1 Section 2.3 - Notice of Meetings 1 Section 2.4 - Quorum 1 Section 2.5 - Organization 2 Section 2.6 |
|
| February 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 26, 2024 ASTRANA HEALTH, INC. |
|
| February 13, 2024 |
AMEH / Apollo Medical Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0308-apollomedicalholdings.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Apollo Medical Holdings Inc Title of Class of Securities: Common Stock CUSIP Number: 03763A207 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate bo |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 31, 2024 APOLLO MEDICAL HOLDINGS, INC. |
|
| February 2, 2024 |
Exhibit 10.1 AMENDMENT NO. 1 to ASSET AND EQUITY PURCHASE AGREEMENT THIS AMENDMENT (this “Amendment”), is entered into as of January 31, 2024, by and among METROPOLITAN IPA, a California professional corporation (“PC Buyer”); APOLLOCARE ENABLEMENT OF CA, LLC, a California limited liability company (“MSO GP Buyer”); NETWORK MEDICAL MANAGEMENT, INC., a California corporation (“MSO LP Buyer” and, tog |
|
| January 26, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF RESTATED CERTIFICATE OF INCORPORATION OF APOLLO MEDICAL HOLDINGS, INC. Apollo Medical Holdings, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify as follows: FIRST: The Restated Certificate of Incorporation of the Corporation (the “Certificate”) is h |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 25, 2024 APOLLO MEDICAL HOLDINGS, INC. |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 19, 2024 APOLLO MEDICAL HOLDINGS, INC. |
|
| January 10, 2024 |
Apollo Medical Holdings January 2024 Powered by Technology. Built by Doctors. For Patients. Exhibit 99.1 Apollo Medical Holdings January 2024 Powered by Technology. Built by Doctors. For Patients. Forward - looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about the |
|
| January 10, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2024 APOLLO MEDICAL HOLDINGS, INC. |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 26, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| January 2, 2024 |
Exhibit 10.1 CERTIFICATE OF DETERMINATION OF PREFERENCES OF SERIES A PREFERRED STOCK OF ALLIED PHYSICIANS OF CALIFORNIA, A PROFESSIONAL MEDICAL CORPORATION Pursuant to Section 401 of the General Corporation Law of the State of California The undersigned, Thomas Lam, M.D., and Paul Liu, M.D., hereby certify that: A. They are the duly elected and acting Chief Executive Officer and the duly elected a |
|
| November 30, 2023 |
Apollo Medical Holdings November 2023 Powered by Technology. Built by Doctors. For Patients. Exhibit 99.1 Apollo Medical Holdings November 2023 Powered by Technology. Built by Doctors. For Patients. Forward - looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about the |
|
| November 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 17, 2023 |
SC 13D/A 1 tm2330684d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 7)* Apollo Medical Holdings, Inc. (Name of Issuer) Common Stock, $0.001 par |
|
| November 17, 2023 |
As filed with the Securities and Exchange Commission on November 17, 2023 As filed with the Securities and Exchange Commission on November 17, 2023 Registration No. |
|
| November 17, 2023 |
Exhibit 10.2 APOLLO MEDICAL HOLDINGS, INC. EMPLOYMENT INDUCEMENT AWARD PLAN STOCK OPTION GRANT NOTICE Apollo Medical Holdings, Inc. (the “Company”), pursuant to its Employment Inducement Award Plan (the “Plan”), hereby grants to the individual listed below (“Participant”), as an inducement to the Participant’s commencement of employment with the Company or a Subsidiary, an option (the “Option”) to |
|
| November 17, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Apollo Medical Holdings, Inc. |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 17, 2023 |
Apollo Medical Holdings, Inc. Employment Inducement Award Plan. Exhibit 10.1 APOLLO MEDICAL HOLDINGS, INC. EMPLOYMENT INDUCEMENT AWARD PLAN ARTICLE I. Purpose This Plan has been established effective as of November 15, 2023, the date of approval of the Plan by the Board. The Plan’s purpose is to enhance the Company’s ability to attract and motivate individuals who are expected to make important contributions to the Company and its Subsidiaries by providing suc |
|
| November 17, 2023 |
Exhibit 10.3 APOLLO MEDICAL HOLDINGS, INC. EMPLOYMENT INDUCEMENT AWARD PLAN RESTRICTED STOCK GRANT NOTICE Apollo Medical Holdings, Inc. (the “Company”), pursuant to its Employment Inducement Award Plan (the “Plan”), hereby grants to the individual listed below (“Participant”), as an inducement to the Participant’s commencement of employment with the Company or a Subsidiary, the number of shares of |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Apollo Medical Hol |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 7, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 7, 2023 |
Exhibit 10.1 THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND INCREMENTAL AGREEMENT THIS THIRD AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND INCREMENTAL AGREEMENT, dated as of November 3, 2023 (this “Amendment”), is made by and among APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the “Borrower”), NETWORK MEDICAL MANAGEMENT, INC., a California corporation (the “Guaranto |
|
| November 7, 2023 |
Amended and Restated Credit Agreement (marked to show changes). Exhibit 10.2 Deal CUSIP: 03768KAA9 Revolver CUSIP: 03768KAB7 Term A Loan CUSIP: 03768KAE1 Delayed Draw Term Loan CUSIP: 03678KAD3 ANNEX A AMENDED AND RESTATED CREDIT AGREEMENT dated as of June 16, 2021 as amended by the FirstThird Amendment to Amended and Restated Credit Agreement dated as of December 20, 2022November 3, 2023 among APOLLO MEDICAL HOLDINGS, INC. as Borrower THE LENDERS FROM TIME TO |
|
| November 7, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 6, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 7, 2023 |
Exhibit 10.1 STOCK REPURCHASE AGREEMENT This STOCK REPURCHASE AGREEMENT (this “Agreement’) is made and entered into as of November 6, 2023 (the “Effective Date”), by and between APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the “Company”), and ALLIED PHYSICIANS OF CALIFORNIA, A PROFESSIONAL MEDICAL CORPORATION, a California professional medical corporation (the “Selling Stockholder” a |
|
| November 7, 2023 |
Exhibit 10.2 STOCK PURCHASE AGREEMENT by and among NETWORK MEDICAL MANAGEMENT, INC., I HEALTH, INC., RONALD BRANDT and ALLISON BRANDT DATED AS OF NOVEMBER 7, 2023 TABLE OF CONTENTS Page Article 1 Purchase and sale; Closing 6 1.1 Purchase and Sale 6 1.2 Closing 6 1.3 Withholding 6 1.4 Disclosure of Excluded Assets.. 6 Article 2 Representations and warranties of the Equityholder and Beneficial Owner |
|
| November 7, 2023 |
Exhibit 99.1 Apollo Medical Holdings, Inc. Announces Definitive Agreement to Acquire Assets of Community Family Care Medical Group IPA, Inc. and Health Plan ALHAMBRA, Calif., Nov. 7, 2023 /PRNewswire/ - Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare com |
|
| November 7, 2023 |
Exhibit 99.2 Powered by Technology. Built by Doctors. For Patients. Apollo Medical Holdings (NASDAQ: AMEH) Third Quarter 2023 Earnings Call Supplement November 7, 2023 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. |
|
| November 7, 2023 |
Exhibit 99.1 Apollo Medical Holdings, Inc. Reports Third Quarter 2023 Results Company to Host Conference Call on Tuesday, November 7, 2023, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., November 7, 2023 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powere |
|
| November 7, 2023 |
Exhibit 10.1 ASSET AND EQUITY PURCHASE AGREEMENT by and among METROPOLITAN IPA, A CALIFORNIA PROFESSIONAL CORPORATION, ApolloCare Enablement of CA, LLC, NETWORK MEDICAL MANAGEMENT, INC., APOLLO MEDICAL HOLDINGS, INC., COMMUNITY FAMILY CARE MEDICAL GROUP IPA, INC., ADVANCED HEALTH MANAGEMENT SYSTEMS, L.P., ACCIE M. MITCHELL AND GLORIA C. MITCHELL, AS CO-TRUSTEES OF THE MITCHELL |
|
| November 3, 2023 |
As filed with the Securities and Exchange Commission on November 3, 2023 As filed with the Securities and Exchange Commission on November 3, 2023 Registration No. |
|
| November 3, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Apollo Medical Holdings, Inc. |
|
| September 13, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 13, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| September 13, 2023 |
Apollo Medical Holdings September 2023 Powered by Technology. Built by Doctors. For Patients. Exhibit 99.1 Apollo Medical Holdings September 2023 Powered by Technology. Built by Doctors. For Patients. This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statements about the Compa ny's business, financ |
|
| September 8, 2023 |
Exhibit 10.1 SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND WAIVER THIS SECOND AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT AND WAIVER, dated as of September 8, 2023 (this “Amendment”), is made by and among APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the “Borrower”), NETWORK MEDICAL MANAGEMENT, INC., a California corporation (the “Guarantor”), each of the banks and |
|
| September 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 8, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Apollo Medical Holdings, Inc. |
|
| August 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Apollo Medical Holdings, Inc. |
|
| August 16, 2023 |
Exhibit 4.5 APOLLO MEDICAL HOLDINGS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20 Debt Securities Table Of Contents Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certificate |
|
| August 16, 2023 |
As filed with the Securities and Exchange Commission on August 16, 2023 As filed with the Securities and Exchange Commission on August 16, 2023 Registration No. |
|
| August 9, 2023 |
Nonqualified Deferred Compensation Plan (effective July 1, 2023). 1 APOLLO MEDICAL HOLDINGS, INC. NONQUALIFIED DEFERRED COMPENSATION PLAN RECITALS This Nonqualified Deferred Compensation Plan (the “Plan”) is adopted by Apollo Medical Holdings, Inc. (the “Company”), a Delaware corporation, for the benefit of its Eligible Individuals. The purpose of the Plan is to offer selected Eligible Individuals who contribute significantly to the future business success of th |
|
| August 9, 2023 |
Exhibit 99.1 Apollo Medical Holdings, Inc. Reports Second Quarter 2023 Results Company to Host Conference Call on Monday, August 7, 2023, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., August 7, 2023 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered he |
|
| August 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Apollo Medical Holdings, I |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to . Commission file number: 001-3 |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Apoll |
|
| August 7, 2023 |
Exhibit 99.2 1 Powered by Technology. Built by Doctors. For Patients. Apollo Medical Holdings (NASDAQ: AMEH) Second Quarter 2023 Earnings Call Supplement August 7, 2023 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| August 7, 2023 |
Exhibit 99.1 Apollo Medical Holdings, Inc. Reports Second Quarter 2023 Results Company to Host Conference Call on Monday, August 7, 2023, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., August 7, 2023 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered he |
|
| July 31, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 31, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| July 31, 2023 |
Exhibit 99.1 Apollo Medical Holdings, Inc. Announces Partnership with IntraCare to Advance Value-Based Care in Texas and Oklahoma ALHAMBRA, Calif., July 31, 2023 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling p |
|
| July 12, 2023 |
Exhibit 99.1 Apollo Medical Holdings, Inc. Signs Definitive Agreement to Acquire Assets of Texas Independent Providers, Expanding Care Partners Business into Houston ALHAMBRA, Calif., July 12, 2023 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered heal |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 (June 13, 2023) APOLLO MEDICAL HOLDINGS, INC. |
|
| June 16, 2023 |
Exhibit 10.1 APOLLO MEDICAL HOLDINGS, INC. EMPLOYEE STOCK PURCHASE PLAN 1. Establishment and Purpose of Plan. This Apollo Medical Holdings, Inc. Employee Stock Purchase Plan (the “Plan”) was adopted by the Board effective April 21, 2023, subject to approval of the Plan by the stockholders of the Company at the 2023 Annual Meeting of Stockholders. The purpose of the Plan is to provide to eligible s |
|
| June 7, 2023 |
Exhibit 99.1 Apollo Medical Holdings June 2023 Powered by Technology. Built by Doctors. For Patients. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial conditi |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 7, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Apollo Medical Holdings, |
|
| May 8, 2023 |
Apollo Medical Holdings, Inc. Reports First Quarter 2023 Results Company to Host Conference Call on Monday, May 8, 2023, at 2:30 p.m. PT/5:30 p.m. ET ALHAMBRA, Calif., May 8, 2023 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company foc |
|
| May 8, 2023 |
exhibit992-apollomedq120 1 Powered by Technology. Built by Doctors. For Patients. Apollo Medical Holdings (NASDAQ: AMEH) First Quarter 2023 Earnings Call Supplement May 8, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 13, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| March 13, 2023 |
apollomedinvestorpresent Apollo Medical Holdings March 2023 Powered by Technology. |
|
| March 1, 2023 |
exh1055-firstamendmentto Exhibit 10.14 42418200 FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT THIS FIRST AMENDMENT TO AMENDED AND RESTATED CREDIT AGREEMENT is dated as of December 19, 2022 (this “Amendment”), by and among APOLLO MEDICAL HOLDINGS, INC., a Delaware corporation (the “Borrower”), NETWORK MEDICAL MANAGEMENT, INC., a California corporation (the “Guarantor”), each of the banks |
|
| March 1, 2023 |
Subsidiaries of Apollo Medical Holdings, Inc. Exhibit 21.1 Subsidiaries Entity Jurisdiction of Incorporation Network Medical Management, Inc. California Apollo Medical Management, Inc. Delaware APAACO, Inc. Delaware Apollo Care Connect, Inc. Delaware ApolloMed Accountable Care Organization, Inc.* California Allied Pacific Hospice, LLC California Allied Physicians ACO, LLC California APCN-ACO, Inc. California 99 Medical Equipment, Healthcare S |
|
| March 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to . Commission file number: 001-37392 Apollo Medic |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 23, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| February 23, 2023 |
apollomedq4-ye2022earnin 1 Powered by Technology. Built by Doctors. For Patients. Apollo Medical Holdings (NASDAQ: AMEH) Fourth Quarter and Year-End 2022 Earnings Call Supplement February 24, 2023 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section |
|
| February 23, 2023 |
Apollo Medical Holdings, Inc. Reports Fourth Quarter and Year-End 2022 Results Company to Host Conference Call on Friday, Feb. 24, 2023, at 5:30 a.m. PT/8:30 a.m. ET ALHAMBRA, Calif., February 23, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered |
|
| February 9, 2023 |
AMEH / Apollo Medical Holdings Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0283-apollomedicalholdings.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Apollo Medical Holdings Inc. Title of Class of Securities: Common Stock CUSIP Number: 03763A207 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate b |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 2, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| January 11, 2023 |
a111x22apollomedinvesto Apollo Medical Holdings January 2023 Powered by Technology. |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 11, 2023 APOLLO MEDICAL HOLDINGS, INC. |
|
| December 16, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 15, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| December 16, 2022 |
Apollo Medical Holdings, Inc. Announces Share Repurchase Program Apollo Medical Holdings, Inc. Announces Share Repurchase Program ALHAMBRA, Calif., December 15, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. (?ApolloMed,? and together with its subsidiaries and affiliated entities, the ?Company?) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, toda |
|
| December 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 30, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 22, 2022 |
CORRESP 1 filename1.htm November 22, 2022 Mr. Abe Friedman, Staff Accountant Division of Corporation Finance Office of Trade and Services United States Securities and Exchange Commission Washington, D.C. 20549 Re: Apollo Medical Holdings, Inc. Form 10–K for the Fiscal Year Ended December 31, 2021 Filed February 28, 2022 File No. 001–37392 Dear Mr. Friedman: This letter is submitted in response to |
|
| November 14, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 8, 2022 |
Apollo Medical Holdings November 2022 Powered by Technology. Built by Doctors. For Patients. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, opera |
|
| November 8, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Apollo Medical Holdin |
|
| November 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 4, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| November 4, 2022 |
Exhibit 99.1 1 Apollo Medical Holdings (NASDAQ: AMEH) Powered by Technology. Built by Doctors. For Patients. Third Quarter 2022 Earnings Call Supplement November 4, 2022 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act |
|
| November 3, 2022 |
Apollo Medical Holdings, Inc. Reports Third Quarter 2022 Results, Raises Revenue, Net Income and EBITDA Guidance for Full-Year 2022 Company to Host Conference Call on Friday, Nov. 4, 2022, at 5:30 a.m. PT/8:30 a.m. ET ALHAMBRA, Calif., November 3, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. (?ApolloMed,? and together with its subsidiaries and affiliated entities, the ?Company?) (NASDAQ: AMEH |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| October 12, 2022 |
Apollo Medical Holdings October 2022 Powered by Technology. Built by Doctors. For Patients. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operat |
|
| October 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 12, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| October 7, 2022 |
October 7, 2022 Mr. Doug Jones, Staff Accountant Division of Corporation Finance Office of Trade and Services United States Securities and Exchange Commission Washington, D.C. 20549 Re: Apollo Medical Holdings, Inc. Form 10?K for the Fiscal Year Ended December 31, 2021 Filed February 28, 2022 File No. 001?37392 Dear Mr. Jones: This letter is submitted in response to comments from the staff (the ?S |
|
| October 6, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 5, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| October 6, 2022 |
EX-99.1 2 exhibit991-pressreleasevomg.htm EX-99.1 Apollo Medical Holdings, Inc. Expands into Nevada and Texas with Acquisition of Valley Oaks Medical Group ALHAMBRA, Calif., October 5, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare c |
|
| September 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 26, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| September 26, 2022 |
Apollo Medical Holdings, Inc. Announces Affiliate?s Entry into Agreement to Acquire All American Medical Group and For Your Benefit ALHAMBRA, Calif., September 26, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. (?ApolloMed,? and together with its subsidiaries and affiliated entities, the ?Company?) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on ena |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Apollo Medical Holdings, I |
|
| August 9, 2022 |
- 1 - 016335.00010 36435896.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of April 12, 2022, by and between Network Medical Management, Inc., a California corporation (the ?Employer?), and Chandan Basho (the ?Employee,? and together with the Employer, collectively referred to as the ?Parties?) to become effective on the ?Effective Date? as set fort |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 4, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| August 4, 2022 |
Strong Q2 2022 financial results as utilization increased to pre-pandemic levels Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. |
|
| August 4, 2022 |
Apollo Medical Holdings, Inc. Reports Second Quarter 2022 Results Company to Host Conference Call Today at 2 p.m. PT/5 p.m. ET ALHAMBRA, Calif., August 4, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. (?ApolloMed,? and together with its subsidiaries and affiliated entities, the ?Company?) (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling pro |
|
| June 22, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 22, 2022 (June 16, 2022) APOLLO MEDICAL HOLDINGS, INC. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-37392 Apollo Medical Holdings, |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 5, 2022 APOLLO MEDICAL HOLDINGS, INC. |
|
| May 5, 2022 |
EX-99.1 2 exhibit991-pressrelease033.htm EX-99.1 Apollo Medical Holdings, Inc. Reports First Quarter 2022 Results Company to Host Conference Call Today at 2 p.m. PT/5 p.m. ET ALHAMBRA, Calif., May 5, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. (“ApolloMed,” and together with its subsidiaries and affiliated entities, the “Company”) (NASDAQ: AMEH), a leading physician-centric, technology-power |
|
| May 5, 2022 |
Apollo Medical Holdings, Inc. Announces Appointment of Chief Strategy Officer and CFO Transition Apollo Medical Holdings, Inc. Announces Appointment of Chief Strategy Officer and CFO Transition ALHAMBRA, CA, May 5, 2022 /PRNewswire/ - Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of |
|
| May 5, 2022 |
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 14, 2022 |
Apollo Medical Holdings March 2022 Powered by Technology. Built by Doctors. For Patients. EX-99.1 2 tm229175d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Apollo Medical Holdings March 2022 Powered by Technology. Built by Doctors. For Patients. This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward - looking statements include any statemen |
|
| March 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 14, 2022 APOLLO MEDICAL HOLDINGS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-37392 95-4472349 (State or Other Jurisdiction (Commission (I.R.S. Employer |
|
| February 28, 2022 |
Subsidiaries of Apollo Medical Holdings, Inc. Exhibit 21.1 Subsidiaries Entity Jurisdiction of Incorporation Network Medical Management, Inc. California Apollo Medical Management, Inc. Delaware APAACO, Inc. Delaware Apollo Care Connect, Inc. Delaware ApolloMed Accountable Care Organization, Inc.* California Allied Pacific Hospice, LLC California Allied Physicians ACO, LLC California APCN-ACO, Inc. California 99 Medical Equipment, Healthcare S |
